Conference Correspondent

Specialized oncology pharmacy programs are playing an ever-increasing role in the complex delivery of care. In this session, panelists discuss the obstacles and successes of specialized oncology pharmacy programs.

In this session, a panel of experts share the Wall Street perspective on the opportunities and challenges ahead for cancer drug developers and healthcare providers.

Healthcare continues to adapt to the economic impact of the COVID-19 pandemic. In this session, industry experts discuss the underlying trends and economic realities of cancer care in the United States and global markets.

The increased complexity of new oncology drugs and the accelerated rate of their approval has led to greater demands from stakeholders across the cancer care continuum. In this session, panelists discuss oncology drug supply chain channels and how they are incorporated in the move to value-based care.

Numerous new innovations in stem-cell transplantation are coming to the market. In this session, experts offer the clinician, manufacturer, and payer perspectives regarding these new therapies.

As one of the largest operational oncology value-based payment models, OCM has been a driving force in cancer

Cancer care is complex and expensive, making a one-size-fits-all approach to drug benefit designs and coverages an unfavorable solution for patients with cancer. In this session, panelists discuss drug benefit reforms and the intended and unintended consequences of the recommended provisions.

With multiple stakeholders playing a key role in value-based contracting, the pharmaceutical industry faces many obstacles. In this session, experts discuss these obstacles and the strategies for overcoming them.

340B is a discount program for low-income areas that increases resources and allows for patient expansion. In this session, panelists discuss the accuracy of pricing, the current state of the program, and future developments.

In this session, industry leaders discuss defining clinical utility for genomic testing and make recommendations to ensure appropriate implementation in cancer care.